basic helix-loop-helix family member e41Genealiases: BHLHB3 · DEC2 · FNSS1 · SHARP1 · hDEC2
Q-omics provides the consensus-scored BHLHE41 profile across patient tissues and cancer cell-line models. BHLHE41 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, BHLHE41 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, BHLHE41 RNA expression shows 19,953 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, KIRC, and LSCC as cancer lineages where BHLHE41 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BHLHE41 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BHLHE41 survival associations across molecular data types. BHLHE41 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BHLHE41 RNA expression–survival associations across cancer types. High BHLHE41 expression shows unfavorable associations in UVM, but favorable associations in BLCA, BRCA, DLBC, HNSC and CESC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for BHLHE41 RNA expression.
This table summarizes BHLHE41 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BHLHE41. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BHLHE41 shows lower tumor expression in COAD, LUAD and KICH and higher tumor expression in KIRC, THCA and KIRP. The KIRC box plot shows higher BHLHE41 RNA expression in tumor versus normal tissue (log2 FC = +3.371, t-test p < 0.001).
This table shows molecular features associated with BHLHE41 in patient tissues and cancer cell lines. In patient samples, BHLHE41 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, BHLHE41 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
